Ziprasidone

CNS Drugs

Volumn 8, Issue 2, 1997, Pages 153-159

  Davis, Rick ^a   Markham, Anthony ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 ISOENZYME; DEXAMPHETAMINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; SEROTONIN 2 RECEPTOR; ZIPRASIDONE;

AMINE TRANSPORT; ANXIETY; BEHAVIOR; CATECHOLAMINE UPTAKE; CLINICAL TRIAL; DENTAL SURGERY; DEPRESSION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MOTOR DYSFUNCTION; NAUSEA; NEGATIVE SYNDROME; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEROTONIN UPTAKE; SHORT SURVEY; SOMNOLENCE;

EID: 0030755827     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708020-00006     Document Type: Short Survey

References (24)

1. Meltzer HY. Role of serotonin in the action of atypical antipsychotic drugs. Clin Neurosci 1995; 3 (2): 64-75
2. Meltzer HY. Pre-clinical pharmacology of atypical anlipsycholic drugs: a selective review. Br J Psychiatry 1996 May; 168 Suppl. 29: 23-31
3. Hesselink JMK, Sambunaris A. Behavioral pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. Int Rev-Psych 1995; 7 (1): 41-53
4. Tandon R, Harrigan E. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Ser Res. In press
5. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88.059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995 Oct; 275: 101-13
6. Bench CJ, Lammertsma AA, Dolan RJ, et al. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology 1993 Sep; 112: 308-14
7. 2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J Pharmacol Exp Ther 1996; 279 (2): 939-47
8. O'Connor R, Harrigan E, Heym J, et al. The efficacy and safety profile of a new antipsychotic, ziprasidone [abstract]. Xth World Congress of Psychiatry; 1996 May 23-28; Madrid
9. Miceli JJ, Hum T, Cole MJ, et al. The pharmacokinetics (PK) of CP-88.059 (CP) in healthy male volunteers following oral (PO) and intravenous (IV) administration [abstract no. PI-78]. 95th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1994 Mar 30-Apr 1; New Orleans, 142
10. Wilner KD, Hansen RA, Johnson AC, et al. Single and multiple dose pharmacokinetics of ziprasidone in healthy males [abstract no. P-2-7]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 38
11. Tensfeldt TG, Wilner KD, Baris B, et al. Steady-state pharmacokinetics of ziprasidone in healthy elderly and young volunteers [abstract]. Annual Meeting of the American Psychiatric Association; 1997 May 16-23; San Diego
12. Prakash C, Kamel A, Anderson W. Absorption, metabolism and excretion of antipsychotic drug ziprasidone in rat and mouse [abstract]. Proceedings of 6th North American International Society for the Study of Xenobiotics Meeting; 1994 Oct 23-7; Raleigh, USA, 107
13. Prakash C, Kamel A, Cui D, et al. Ziprasidone metabolism and cytochrome P450 isoforms [poster]. Annual Meeting of the American Psychiatric Association; 1997 May 16-23: San Diego
14. Wilner KD, DeMattos SB, Anziano RJ, et al. Lack of CYP2D6 inhibition by ziprasidone in healthy volunteers [poster]. Annual Meeting of the American Psychiatric Association; 1997 May 16-23; San Diego
15. Wilner KD, Anziano RJ, Tensfeldt TG, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium [abstract no. P-2-8]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 38
16. Muirhead GJ, Holt PR, Oliver S, et al. The effect of ziprasidone on steady-state pharmacokinetics of a combined oral contraceptive [abstract P-2-6]. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 38
17. Wilner KD, Hansen RA, Folger CJ, et al. Effects of cimetidine or Maalox® on ziprasidone pharmacokinetics [poster]. Annual Meeting of the American Psychiatric Association; 1997 May 16-23; San Diego
18. Reeves KR, Harrigan EP. The efficacy and safety of two fixed doses of ziprasidone in schizophrenia and schizoaffective disorder [poster]. 20th Collegium internationale Neuro-Psychopharmacologicum (C.I.N.P.) Congress; 1996 Jun 23-27; Melbourne
19. Harrigan E, Morrissey M, Ziprasidone Working Group. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder [poster]. 20th Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) Congress; 1996 Jun 23-27; Melbourne
20. O'Connor R, Harrigan E, Heym J, et al. The efficacy and safety profile of a new antipsychotic, ziprasidone [poster]. VIIIth Congress of the Europe an College of Neuropsychopharmacology; 1995 Sep 30-Oct 4; Venice
21. Daniel D, Reeves K, Harrigan EP, et al. The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder [abstract]. Schizophr Res 1997; 24: 204
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association. 1987
23. Brook S, Swift R, Harrigan EP. The tolerability and efficacy of intramuscular ziprasidone [poster]. Annual Meeting of the American Psychiatric Association; 1997 May 16-23; San Diego
24. Wilner KD, Anziano RJ, Johnson AC, et al. Anxiolytic effects of ziprasidone compared with diazepam and placebo prior to dental surgery [poster]. 20th Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) Congress; 1996 Jun 23-27; Melbourne